Cambridge, MA (Press Release) – Millennium: The Takeda Oncology Company with its parent com­pany, Takeda Pharma­ceu­tical Company Limited (TSE:4502), today announced that the U.S. Food and Drug Admin­istra­tion (FDA) has approved VELCADE® (bor­tez­o­mib) for the retreatment of adult patients with multiple myeloma (MM) who had pre­vi­ously responded to VELCADE ther­apy and re­lapsed at least six months fol­low­ing completion of prior VELCADE treat­ment. The labeling update in­cludes dosing guidelines as well as safety and efficacy findings for the use of VELCADE as a single agent or VELCADE in com­bi­na­tion with dexa­meth­a­sone in patients …

Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening
Results to Form Basis of Regulatory Filings Beginning in 1H 2015

Thousand Oaks, California and South San Francisco, California (Press Release) Amgen (NASDAQ:AMGN) and its sub­sid­i­ary, Onyx Pharma­ceu­ticals, Inc., today announced that a planned interim analysis demon­strated that the Phase 3 clin­i­cal trial ASPIRE (CArfilzomib, Lena­lido­mide, and DexamethaSone versus Lena­lido­mide and Dexamethasone for the treat­ment of PatIents with Relapsed Multiple MyEloma) met its pri­mary end­point of pro­gres­sion-free survival (PFS). Patients treated with Kyprolis® (car­filz­o­mib) for Injection in com­bi­na­tion with Revlimid® (lena­lido­mide) and low-dose dexa­meth­a­sone (KRd) lived sig­nif­i­cantly longer without their disease worsening (median 26.3 months) compared …

Six Data Presentations at the European Hematology Association's 19th Congress

Natick, Massachusetts (Press Release) - Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clin­i­cal-stage pharma­ceu­tical com­pany, today announced initial Phase 1 data from patients with multiple myeloma treated with Karyopharm's lead selective inhibitor of nuclear export (SINE), Selinexor (KPT-330), in com­bi­na­tion with "low-dose" (20 mg twice weekly) dexa­meth­a­sone. Among eight patients, the best responses were one stringent com­plete response (sCR), three partial responses (PRs), two minor responses (MRs), one pro­gressive disease and one non-evaluable. Accordingly, the clin­i­cal benefit response rate (sCR+PR+MR) is 75% and the over­all response rate (sCR+PR) is 50%. These new results will be …

• Results show adding LBH589 to bortezomib and dexamethasone significantly improved PFS by 37%, meeting Phase III study primary endpoint[1]
• Median PFS increased by 4 months (12 months in LBH589 arm versus 8 months in placebo arm); effect of LBH589 observed across all patient subgroups[1]
• Most people with multiple myeloma will relapse or become refractory; if approved, LBH589 will be first in its class of anticancer agents available to this population[1]
• Based on these data, US

 …

New York (Press Release) - Stemline Thera­peutics, Inc. (Nasdaq:STML) an­nounced to­day that data demonstrating SL-401 ef­fi­cacy in mul­ti­ple myeloma (MM) pre­clin­i­cal models will be pre­sented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30-June 3, 2014 in Chicago, IL.

In col­lab­o­ration with Stemline, ex­per­i­ments con­ducted at the Dana-Farber Cancer In­sti­tute, Boston, MA, by Drs. Dharminder Chauhan and Kenneth Anderson and their MM re­search team dem­onstrated that Stemline's clin­i­cal can­di­date SL-401 sig­nif­i­cantly de­creased the viability of malignant cells by targeting neighboring plas­ma­cytoid dendritic cells (pDCs) in the tumor …

Designation granted for inves­ti­ga­tional agent elotuzumab in com­bi­na­tion with lena­lido­mide and dexa­meth­a­sone for treat­ment of mul­ti­ple myeloma in patients who have re­ceived one or more prior ther­a­pies

Princeton, NJ and North Chicago, IL (Press Release) – Bristol-Myers Squibb Com­pany (NYSE:BMY) and AbbVie (NYSE:ABBV) to­day an­nounced that the U.S. Food and Drug Admin­istra­tion (FDA) has granted elotuzumab, an inves­ti­ga­tional humanized mono­clonal anti­body, Break­through Therapy Desig­na­tion for use in com­bi­na­tion with lena­lido­mide and dexa­meth­a­sone for the treat­ment of mul­ti­ple myeloma in patients who have re­ceived one or more prior ther­a­pies. The desig­na­tion is based on findings from a ran­dom­ized Phase 2, open-label study that eval­u­ated two dose levels of elotuzumab in com­bi­na­tion with lena­lido­mide and low-dose dexa­meth­a­sone in pre­vi­ously-treated …

Rochester, MN (Press Release) – In a proof of principle clin­i­cal trial, Mayo Clinic researchers have dem­onstrated that virotherapy – destroying cancer with a virus that infects and kills cancer cells but spares normal tissues – can be effective against the deadly cancer multiple myeloma. The findings appear in the journal Mayo Clinic Proceedings.

Two patients in the study received a single in­tra­venous dose of an engi­neered measles virus (MV-NIS) that is selectively toxic to myeloma plasma cells. Both patients responded, showing reduction of both bone marrow cancer and myeloma protein. One patient, …